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Natural products have proven to be a good source of anticancer drugs since the 
1940’s. In fact, they have influenced the creation of 65% of all 246 anticancer drugs since 
that time. Fungi in particular provide an almost untapped source of compounds with 
promising bioactivity. To access compounds from natural products, an extraction and 
purification process using flash chromatography, and high performance liquid 
chromatography is needed. Characterization of those compounds is done using high-
resolution mass spectrometry and NMR spectroscopy. These methods were used to 
isolate and characterize six known compounds that were added to an in-house database. 
Leporin B, leporin C, austdiol and 7-epi-austdiol were all isolated from Scytalidium 
cuboideum strain 68345. Leporin B has specifically proven to be effective in different 
aspects of research including, its effect on hexokinase II and it has shown potential as a 
cytotoxic compound towards cancer cells.  The re-isolation of leporin B has increased the 
in-house supply for use in future experimentation. Through the re-isolation of leporin B, 
leporin C was found. Leporin C is new to natural product; however, the compound has 
been previously synthesized, and it only differs from the structure of leporin B by one 
oxygen atom. Austdiol and 7-epi-austdiol were also isolated during the search for leporin 
B. Fungal strain MSX74367 was also studied, and yielded, 9-O-methylbostrycoidin and 
8-O-methylfusarubin. The benzoisoquinoline structure, the core structure of 9-O-
methylbostrycoidin and 8-O-methylfusarubin, is new to the current in-house database of 
over 300 compounds isolated from fungi. Mass defect analysis and high-resolution mass 
spectrometry were used in an effort to isolate other benzoisoquinoline type compounds 
through mass guided fractionation; however, the process was unsuccessful in finding 
additional analogues. In total, six compounds were found from two different strains of 
fungi, all of which were new to an in-house database. The fungus Scytalidum cuboideum, 
in particular, produced leporin B and leporin C, which was isolated for the first time from 
a natural source.  
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CHAPTER I 
 
INTRODUCTION 
 
 
Cancer 
Cancer is one of the leading causes of death in the world today. People have come 
to fear the very name, because it is known to be an extremely difficult disease to treat. 
But how far back has cancer been affecting life? According to the American Cancer 
Society, cancer was first described in an Egyptian textbook called the Edwin Smith 
Papyrus around 3000 BC (1). The book expressed the existence of a few different types 
of cancer and how to remove them using surgery, however it also expresses that there is 
not a treatment for cancer. The word cancer was not portrayed until Hippocrates, 
somewhere between 460 and 370 BC (1). At the time, Hippocrates used carcino and 
carcinoma to describe different types of cancer. The words were later translated into 
Latin, which became the word cancer, which is the descriptive word for crab, the 
reference to how the cancer appeared with its protruding features. Since the first 
discovery of cancer, people have tried to understand it and a number of theories were 
expressed in order to describe the disease. When Hippocrates studied cancer, he 
explained it as the result of an imbalance in the four humors of the body, which included: 
blood, phlegm, yellow bile and black bile (2). That theory was later replaced by the 
Lymph theory, which said that the formation of cancer was the result from fermenting
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and degenerating lymph that flows through the body (2). The Blastema theory was next, 
fermenting and degenerating lymph that flows through the body (2). The Blastema theory 
was next, expressing cancer was made up of cells and not lymph and that those cells were 
created from other cells (2). The chronic irritation theory followed, explaining that cancer 
was due to chronic irritation and that it spread through the body as a liquid (2). A German 
surgeon, who expressed the spread of cancer through malignant cells, later disproved 
aspects of this theory. Other theories included the trauma theory and the infectious 
disease theory.  
The trauma theory was based on the idea that trauma caused cancer, but was later 
disproved through animal testing (2). The infectious disease theory expressed cancer was 
contagious (2). As of today, we know that there is a long list of things that can be the 
cause of cancer. Some of those compounds include: coal tars, hydrocarbons, benzene, 
aniline, asbestos, ionizing radiation and some viruses (3). These aspects explain the 
initiation; it is what they do to the cells in the body that has been the unanswerable 
question until the past century. Cancer is the proliferation of cells that have damaged 
DNA (3). Cells in the body have a specific mechanism that causes apoptosis in cells that 
have damaged DNA (3). Cancer occurs where these cells do not perform apoptosis (3). 
The rapid growth of these cells with damaged DNA can invade into various areas of the 
body and affect the function of vital organs, leading to death. One reason for the 
difficulty in finding a treatment for cancer is that a number of cells can mutate and copy 
itself, therefore, cancer can start anywhere in the body. This aspect leads to cancers of the 
skin, bones, lungs, breast, colon, blood and other areas of the body. There are three 
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different treatments that can be used in the fight against cancer including surgery, 
chemotherapy and radiation (4). Surgery is a method used when trying to remove tumors, 
the cancerous cells. Chemotherapy is a method where compounds that are toxic to rapidly 
dividing cells are infused into the body in the hopes of killing the cancer cells. Radiation 
is a method that uses x-rays to target a specific area of the body and kill the cells in that 
area (5). Based on the type of cancer and the extent to which it has grown, these methods 
can be used in varying combinations. However, these methods are not always effective.  
In terms of statistics, cancer is one of the leading causes of death worldwide. In 
2012 there were approximately 14 million new cases of cancer worldwide and 8.2 million 
deaths related to cancer (6). As of 2016, it is believed that there will be 1,685,210 cancer 
cases and 595,690 cancer related deaths in the United States alone (7). Even with great 
strides to reduce the effects of cancer, death rates are still increasing in the US in cancers 
of the liver, pancreas and uterine corpus. With the reduction of deaths due to heart 
disease, cancer is also becoming the leading cause of death in a number of states. Finding 
a potential cure or treatment for this disease has become increasingly significant as time 
goes on, and one front that may lead to active drug compounds for use as 
chemotherapeutics is natural products. 
Natural Products 
Natural products chemistry can produce active compounds for drug development. 
Of the three approaches to cancer treatment, chemicals that can be infused in the body are 
effective at attacking cancer cells that have metastasized. The interaction that nature’s 
compounds have with enzymes and proteins of living tissue allow those chemicals to be 
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effective active ingredients for different drugs. From a statistical perspective, of 1562 
newly approved drugs from 1981-2014, 4 % come from unaltered natural products, 21 % 
from natural product derivatives, and 1 % from botanical drugs (8). Looking at the 246 
anticancer drugs ranging from the 1940's to 2014, 12 % come from unaltered natural 
products and 25 % from natural product derivatives (8). Looking at best selling drugs 
today, natural products makes up nearly 45 % (9). Nature has provided the chemistry that 
can aid in future drug development, but it needs to be further studied.  
Fungi 
Fungi are diverse in species and they can be grown with relative ease. Therefore, 
isolation of compounds from fungal samples is a good start in the search for potential 
anticancer drugs. Fungi produce interesting chemistry that have proven useful in the field 
of drug discovery and development, and there is such a large variety of fungal samples 
around the world to be sampled that the possibility for new drugs is almost endless. There 
are nearly 135,000 species of fungi that have been described out of the believed 1.5-5.5 
million species in the world (9). From the research done on those fungi, secondary 
metabolites have provided compounds such as penicillins and cephalosporin, 
cyclosporine A, statins, echinocandin B, fingolimod, lentinan, methergin, and 
strobilurins. These compounds are the active ingredients that make up some antibiotics, 
immunosuppressants, cholesterol-lowering agents, antifungals, multiple sclerosis 
treatments, anticancer drugs, and treatments for hemorrhage and fungicides, respectively 
(10). These secondary metabolites can be affected by the environment, leading to fungi 
around the world producing different secondary metabolites to respond to environmental 
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changes. This is where close work with Mycosynthetix comes in. Mycosynthetix is a 
small business that collects and grows various strains of fungi from around the world. Dr. 
Cedrick Pierce, Mycosynthetix CEO, has provided the ability to access a library of over 
55,000 species of filamentous fungi, each of which have the potential of producing an 
average of three unique compounds (11). To put that number in comparison, literature 
shows less than 24,000 metabolites reported from fungi. Natural products chemistry has 
only scratched the surface of fungal metabolites and further study is needed for the 
advancement of medicinal chemistry. 
History of Leporin  
 Leporin A was first isolated from sclerotia of Aspergillus leporis that was 
growing on white-tailed jackrabbit dung in 1991 (12). The compound was tested and 
showed moderate activity against corn earworm, helicoverpazea, and mild activity as an 
antibacterial compound. The compound was fully synthesized in 1996 (13). Later on in 
2003, leporin B was isolated from a fungal strain in Victoria Mexico (14). It was tested 
initially as a compound that would decrease the activity of Hexokinase II, an enzyme that 
alters sugars as they enter the cell (14). This can be a problem with diabetic patients that 
have too much sugar in their cells and low blood sugar. Therefore, leporin B decreased 
the activity of Hexokinase II so that the sugar molecules can enter back into the blood 
stream. Leporin A did not show activity in this regard, showing the importance in 
changing a structure by one side chain. Leporin A and B have the same core structure and 
side substituents with the exception being the side chain on the nitrogen, shown in (Fig. 
1). Leporin A has a methoxy group on the nitrogen and leporin B has an alcohol group on 
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the nitrogen. Leporin B was later isolated from the fungus Scytalidium cuboideum (15). 
The compound was tested for its activity against breast, lung, and astrocytoma cancer cell 
lines. The activity of leporin B against these three cancer cell lines was only an order of 
magnitude lesser from the activity of the positive control camptothecin (15). Therefore, 
we hypothesized further study of leporin B could lead to more active analogues.  
 
Figure 1. Structures of Leporin A, Leporin B, and Leporin C Respectively (13) 
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CHAPTER II 
 
METHODOLOGY 
    
             
  Flash chromatography is an effective tool for the initial separation of 
compounds. This method uses normal phase silica columns to separate compounds based 
on polarity. This process takes an extract that can be anywhere from 20 mg to one g, and 
it creates a number of fractions in less time than it would take using other methods (16). 
The solutions used start with 100 % hexane and go to 100 % chloroform and finally to 
100 % methanol. The small scale (10 g of rice and 20 mL of H2O) fungal samples 
typically use four gram columns that allow for 20 mg-400 mg of sample to be injected. 
The stationary phase is based on silica gel that allow the attachment of polar or nonpolar 
groups, allowing for normal or reverse phase columns to be made. Silica is also used due 
to its ability to refine the separation between closely eluting compounds, decreased back 
pressure on the instrument, and allow higher sample concentrations which reduces the 
solvent needed and therefore reducing solvent evaporation time. High performance liquid 
chromatography preparative columns, on the other hand, can only handle approximately 
and it takes time and solvent to clean. Therefore, flash chromatography is a useful first 
stage separation of an extract.  
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HPLC is a liquid chromatography technique that can separate compounds based 
on size, shape, and charge. The difference between flash chromatography and HPLC is 
efficiency HPLC has more selectivity and separates compounds using retention time 
more completely, because the columns are packed more tight and the columns are longer, 
which allows for more interaction between the compound and the stationary phase of the 
column (17). This process is used to more accurately purify compounds from fractions 
that are created by flash chromatography. In relation to fungal sample purification, HPLC 
typically uses reverse phase columns. Reverse phase chromatography uses a non-polar 
stationary phase, made with silica beads coated in long carbon chains, which allow polar 
compounds to elute off the column first and nonpolar compounds to elute at the end of a 
chromatogram. The HPLC system is also made to allow for higher pressures to be used 
for different samples. HPLC is the main method used for purification in fungal extract 
analysis, and when the sample is pure, ultra-performance liquid chromatography can be 
used to confirm purity. UPLC operates similarly to HPLC and flash chromatography, but 
it uses less sample. Once all purification is performed and a pure sample is obtained, 
analysis can be done using mass spectrometry and nuclear magnetic resonance.  
Analytical methods such as mass spectrometry (MS) and nuclear magnetic 
resonance (NMR) are used for their high sensitivity and ability to provide essential 
aspects of a compound for identification. Mass spectrometry takes a sample, ionizes that 
sample, sends it through a mass analyzer, and finally the ions made are sent to a detector 
to provide a spectrum for analysis. There are a number of mass spectrometer injection 
methods, such as electron ionization, chemical ionization, electrospray ionization and 
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matrix assisted laser desorption ionization. Each ionization method has its advantages and 
disadvantages, but electrospray ionization is the ionization of choice for most natural 
product compound analysis (18, 19). The main idea of a mass analyzer is the rotation of 
ions in a chamber using magnetic poles. Ions are selected based of magnitude of rotation 
created by the magnetic field. The magnetic poles can be in groups of 4, a quadrupole, or 
8, an octupole. Mass analyzers can also include ion collision cells that produce MS/MS 
results and an orbitrap that produces separation of signal that hits a detector. Finally there 
is the detector that produces the spectrum that is used for analysis. Mass data can be used 
to determine the molecular weight of a compound and MS/MS data that can provide 
structural data for use in dereplication, a method for filtering data showing known 
compounds. The accurate mass obtained can be compared to NMR data to allow the 
characterization of compounds found from purified organic extracts of fungal samples.  
A nuclear magnetic resonance spectrometer (NMR) is an instrument that uses a 
magnet and radio frequency detector to monitor the signal produced from protons of 
different chemical environments as they relax through energy states. The data created 
provides the number of protons in a compound through the use of integrals, the chemical 
environment of protons using chemical shifts, connectivity of protons using coupling 
constants and the relation of protons through space using relaxation effects. The 
combination of data from mass spectrometry, molecular mass, and NMR, proton 
environments, can provide almost everything needed to solve the structure of a pure 
compound.  
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MS and NMR provide a large portion of the data needed to solve the structure of a 
compound, but there are other pieces of data that allow for structure elucidation such as: 
ultraviolet spectroscopy (UV), infrared spectroscopy (IR), and x-ray crystallography (17). 
Ultraviolet spectroscopy provides data about conjugation, or pi-bond character and ring 
structures. IR spectroscopy data are used to determine the presence of certain functional 
groups. X-ray crystallography is the final piece of data that essentially gives a picture of 
the molecule. The combination of all of these analytical methods with NMR and MS 
allows for accurate structure elucidation of a compound.  
Mass spectrometry is an effective tool when it comes to determining the structure 
of specific compounds found in a sample. There are cases where a specific type of 
compound or structure is being isolated, and mass spectrometry can be used to determine 
the presence of that compound or not. Therefore, mass spectrometry data can be used at 
various stages of the purification process in order to obtain the compound of interest 
through specific fractionation. There are methods for narrowing the search of the 
complicated mass spectrometry data, including the use of precursor ion and neutral loss 
scanning techniques, however, these techniques are not completely effective in 
highlighting both the common and uncommon metabolites of various drug compounds. 
Therefore, in 2003, mass defect filtering was expressed as a potential method for the 
determination of both common and uncommon metabolites from compounds of interest 
(20). It was determined that a specific algorithm could analyze the non-integral portion of 
the m/z value and reduce the cluttered high resolution mass spectrometry data to 
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metabolites that are more related structurally. This method is important due to its ability 
to provide masses that correlate in structure through metabolic pathways.  
 Mass defect filtering uses a set of parameters to sift through complex liquid 
chromatography high resolution mass spectrometry data to isolate metabolite ions from a 
biological matrix while at the same time, excluding the interference ions that do not 
correlate to the parent molecule in terms of mass defect values (20). This process reduces 
the background noise that is present in complex samples, thus allowing for the data of 
interest, analogues of a specific molecule, to be isolated without time consuming and 
tedious manual interpretation. To put this technique in perspective of a real world 
situation, say that the compound of interest was glucose, C6H12O6 with a mass of 
180.063385 Da. Glycolysis of glucose leads to the production of glucose-6-phosphate, 
C6H11O9P with a mass of 258.015167 Da. The mass difference of these compounds is 
77.951782 Da, which correlates to the difference in HPO3. The two compounds have the 
same core structure, but differ by the addition of a side substituent. If the mass spectrum 
of glucose-6-phosphate was being analyzed, the mass for glucose could be found in the 
mass spectrum due to the fact that it is an analogue of glucose-6-phosphate. However, 
searching for analogues of the parent compound in the complex data would take time and 
there is the potential for human error. This is where mass defect analysis comes in. The 
algorithm can analyze previously obtained mass data and select the specific peaks that 
correlate to a mass defect range to obtain potential analogues. The first step in mass 
defect analysis is to determine the mass defect, which is defined by the subtraction of the 
closest integer value from the exact mass. In the case mentioned above, that number is 
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defined as the change in mass minus the closest integer value, or 77.951782 – 78 = - 
0.048218 Da. That number is converted to mDa, which would be 48.218 mDa. Even 
though the difference in the masses of the compounds was approximately 78 Da, the 
mass defect difference in the molecules changed by less than 50 mDa. This shows that an 
analogue of a parent molecule can have a large mass difference; however, the mass defect 
is relatively small. Based on this analysis, parameters can be set to search for analogues 
of a parent molecule. Mass defect parameters can be set once, and for the purpose of this 
paper, the mass defect was set to less than 50 mDa. This parameter was chosen due to the 
various metabolite ions that fall within that range. Examples of this include: 
“hydroxylation changes the mass defect by -5 mDa, dehydrogenation by -16 mDa, 
demethylation by -23 mDa, glucuronidation by +32 mDa, and sulfation by -43 mDa” 
(20).   
 Mass defect filtering is a different approach to drug metabolite screening; 
however, it is complementary to the existing methods of precursor ion and neutral loss 
analysis (20). The advantage of mass defect over these methods is the use of 
instrumentation. Mass defect analysis uses a common accurate mass analysis method, 
whereas the other techniques require the use of a triple-quadrupole or a hybrid triple-
quadrupole-linear ion trap mass spectrometer and some prior knowledge of the parent 
molecule (20). Mass defect analysis can take previously acquired high resolution mass 
spectrometry data and analyze it using a mathematical approach to obtain the compound 
masses of interest.   
13 
 
CHAPTER III 
 
EXPERIMENTATION 
 
Organic compounds were extracted from filamentous fungi that were grown on 
rice media. Fungal strains MSX68345 and MSX74367 had 60 mL 1:1 CHCl3 : CH3OH 
added to it, and the mixture was cut up into small protions (21). The fungal samples were 
shaken at 100 rpm in their flask overnight, approximately 16 hr (21). The mixture was 
filtered using vacuum filtration and 90 mL CHCl3 and 150 mL deionized H2O were 
added (21). The mixture was stirred for 30 min and then transferred to a separatory 
funnel. The bottom organic layer was drawn off and dried down under vacuum. An 
aqueous sample was taken from the top layer of the separatory funnel and dried down 
under N2 gas. The aqueous fraction was stored for further analysis. The organic fraction 
was reconstituted in 100 mL of 1:1 MeOH : MeCN and 100 mL of hexanes (21). The 
solution was transferred to a separatory funnel and shaken approximately 20 times. The 
bottom organic layer and top hexane layer were separately dried under vacuum, 
transferred to pre-weighed vials, and dried under N2 gas lines.  
14 
 
Dried organic fractions were sent off for cytotoxicity against cancer cell lines, 
using approximately 0.5 mg of sample. The samples were tested against MDA-MB-435, 
MDA-MB-231 and OVCAR3, which correspond to human melanoma cancer cells, 
human breast cancer cells and human ovarian cancer cells respectively (22). Data from 
cytotoxicity testing was reported as percent survival in concentrations of 20 μg/mL and 2 
μg/mL for each of the three cell   lines. Samples showing less than 50 % survival were 
chosen to be further purified, prioritizing the smaller percent survivals. Cytotoxicity 
values can be reported as IC50 values when the compound is pure. This value represents 
the concentration of sample needed to kill or inhibit the growth of half of the cells in an 
assay. Therefore, lower IC50 values show better cytotoxicity results. Chosen cytotoxic 
samples were analyzed through dereplication, in order to focus resources on samples with 
promising new chemistry.  
Dereplication uses ultra-performance liquid chromatography-photodiode array-
high-resolution tandem mass spectrometry (UPLC-PDA-HRMS-MS/MS) with samples at 
a concentration of 2 mg/mL and compares the MS/MS data in positive and negative mode 
(23). To compare new mass data with previously identified natural products, a database 
was used that includes natural product structures, retention times, UV data, accurate mass 
and ten MS/MS peaks. Mass data from organic extracts of fungal samples can be 
compared with previously isolated compound mass data to determine the presence of 
know structures. Organic fractions with little to no correlation with the in house database 
of over 300 compounds were further prioritized over other fractions. This process allows 
for faster analysis of compounds in order to find new structures as opposed to re-isolating 
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known structures. Dereplication is also used to determine the existence of specific 
compounds for future study, such that if a specific compound was being searched for, the 
mass data from the organic fraction would show the presence of that compound in the 
sample. This technique is an effective tool in determining which samples should be 
further studied. 
Organic extracts that showed good cytotoxicity and the potential for new natural 
products were pushed forward. The crude organic extract of MSX68345 and MSX74367 
fungal strains were purified using normal phase flash chromatography using mobile 
phase that was changed from hexane to chloroform to methanol. The large scale organic 
fraction from MSX68345 was dissolved in a mixture of CHCl3:MeOH and adsorbed on 
Celite. The sample was fractionated using flash chromatography on a 24 g silica column 
with a flow rate of 35 ml/min. The flash chromatography analysis was done using 1908 
mg of sample with a hexane to chloroform to methanol gradient over a 25 minute 
chromatogram. The chromatogram provided 12 fractions (Fig. 2), with the addition of a 
fraction that was created when a compound could only be dissolved using water from the 
last fraction. From this flash chromatography analysis, four of the fractions were further 
purified using HPLC. Fraction four from the flash chromatography of the large scale 
MSX68345 was analyzed through HPLC using the C-18 reverse phase Atlantis T3 
column using a 60 % isocratic gradient of acetonitrile water over the course of 30 
minutes with a 17.06 mL/min flow rate. That purification chromatogram produced 16 
fractions (Fig. 2). All 16 fractions were analyzed through high resolution mass 
spectrometry. The data collected from the mass spectrometry analysis allowed for the 
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identification of two fractions that may have contained leporin B, due to the mass being 
352.19083 and 352.19080 amu for the two fractions. UPLC data showed that the 
fractions were pure enough to analyze via NMR. The NMR data was compared to the 
NMR data previously published for leporin B, which proved to be a match. When 
comparing the NMR data for fractions 13 through 15, it was determined that they were 
both leporin B. However this was a problem because the HPLC chromatogram showed 
the fractions as different peaks. Peaks in the HPLC chromatogram were all tested using 
NMR, and it was determined that the guard filter for the T3 column was not clean. The 
contaminant on the guard filter for the column caused the peaks to split where they 
should not have. Therefore the fractions were tested with NMR to confirm which peaks 
had the same compound. Fractions with the same compound based on NMR data were 
combined and further purified. Thus, fractions 13, 14 and 15 were combined to produce 
18 mg of sample, which was purified using the HPLC with the C-18 reverse phase 
Atlantis T3 column. The gradient used was 65-100% acetonitrile water over 30 minutes, 
and four fractions were collected with a flow rate of 17.06 mL/min. Pure leporin B was 
obtained in the third fraction and confirmed with NMR data. Therefore, an additional 7 
mg of pure leporin B was added to the current supply of less than 3 mg. Looking back at 
the HPLC purification from fraction four of the large scale, NMR data of fractions four 
through six showed similarities to each other and to the proton NMR of leporin B. Mass 
data for the fractions showed masses of 336.195 amu, which is a difference from leporin 
B by an oxygen. Therefore, the fractions were combined and further purified to produce 
seven fractions. This purification used the Atlantis T3 reverse phase C-18 column with a 
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55 % acetonitrile water isocratic gradient over 70 minutes. Proton and carbon NMR 
experiments were performed on fraction one to provide the structure of leporin C, which 
is new to natural products, but it is a known compound (13). This data showed the need 
for further analysis of fractions from MSX68345 due to the potential for additional 
analogues of leporin B.  
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MSX68345 Purification 
 
 
 Figure 2. Purification Fractions for MSX68345 
Further analysis of the fungus was done by looking at fraction six from the large 
scale flash chromatography. The fraction was analyzed through HPLC on the C-18 
reverse phase Gemini column with a 55-90 % acetonitrile water gradient over 30 min. A 
flow rate of 21.24 mL/min was used to create 24 fractions. NMR data of the fractions did 
not show signs of the leporin core structure, and the fractions were set aside. Fraction 
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seven from the same large scale flash chromatography analysis was purified on HPLC 
using the reverse phase C-18 Gemini column with a 5-30 % acetonitrile water gradient 
over 20 min, and then 30-100 over the last 10 minutes of the chromatogram. There were 
13 fractions produced using a flow rate of 21.24 mL/min. Analysis of the fractions 
showed interesting UV data from the HPLC chromatogram, and some fractions formed 
crystals as they dried down. The crystals were analyzed to show the presence of austdiol 
and 7-epi-austdiol through x-ray crystallography. Finally, fraction 8 from the same large 
scale was purified on the HPLC using the C-18 reverse phase Gemini column with a 
gradient of 20-100 % acetonitrile water over the course of 20 min in order to produce 17 
fractions using a flow rate of 21.24 mL/min. Proton NMR and mass data did not show the 
presence of the leporin core structure, and therefore the fractions were set aside. 
Mycosynthetix fungi 74367 was another fungus of interest. The screener scale 
sample was fractionated using flash chromatography on a 4 g silica column with a flow 
rate of 18 ml/min. The flash chromatography analysis was done using 135 mg of sample 
with a hexane to chloroform to methanol gradient over an 18 minute chromatogram to 
create three fractions (Fig. 3). The third fraction was fractionated further using the HPLC. 
The purification used the Gemini C-18 reverse phase column with a 20-100 % 
acetonitrile water gradient over 20 minutes with a flow rate of 21.24 mL/min to create 
nine fractions. High resolution mass spectrometry and proton NMR experiments were 
performed on the fractions created. Fraction three was determined to be 9-O-
methylbostrycoidin, a known compound confirmed through the use of the dictionary of 
natural products. This led to the search for benzoisoquinoline type structures. Therefore, 
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fraction one was further purified due to its similar proton NMR. Fraction one was 
purified on the HPLC using the Luna PFP reverse phase semi-prep column using a 30-55 
% acetonitrile water gradient over 20 min with a 4.6 mL/min flow rate. The purification 
produced four fractions, which were analyzed using HRMS and proton NMR data to 
show the presence of 8-O-methylfusarubin in fraction three. The compound is known and 
does not contain a pyridine ring in the structure.  Further analysis of the remaining 
fractions was needed to determine if other pyridine ring structures were present in 
MSX74367, however material was too low for further purification. Therefore, a large 
scale growth of MSX74367 was extracted and analyzed, looking for the 
benzoisoquinoline structure.  
The large scale MSX74367 growth was fractionated using flash chromatography 
on a 24 g silica column with a flow rate of 35 ml/min. The flash chromatography analysis 
was done using 1243.12 mg of sample with a hexane to chloroform to methanol gradient 
over a 40 minute chromatogram to create 10 fractions (Fig. 4). The fifth and sixth 
fractions were fractionated further using the HPLC due to mass analysis of the fractions 
showing a potential for benzoisoquinoline structures. Fraction five was purified using the 
Gemini C-18 reverse phase column with a 40-100 % acetonitrile water gradient over 30 
min with a 21.24 mL/min flow rate to create nine fractions. Fraction six was purified 
using the Gemini C-18 reverse phase column with a 20-100 % acetonitrile water gradient 
over 20 min at a flow rate of 21.24 mL/min to create 11 fractions. HRMS and NMR 
analysis showed the presence of 9-O-methylbostrycoidin in fraction four. Other 
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analogues of the benzoisoquinoline structure were not found in any of the fractions, and 
the sample was set aside.  
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MSX74367 Purification 
 
 
Figure 3. Purification Fractions for MSX74367 
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Large Scale MSX74367 Purification 
 
 
Figure 4. Purification Fractions for MSX74367   
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CHAPTER IV 
 
LEPORIN 
 
 
Introduction/Past Isolation 
 
Scytalidium cuboideum (MSX 68345) is a filamentous fungus that was studied 
and determined to produce leporin B (2) and purpactin A (3), along with a new 
compound spiroscytalin (1) (15). Of these compounds, compound (2) and (3) were found 
to be active against a panel of cancer cell lines. One of those compounds was purpactin A 
(3). The second one was leporin B (2), which is a N-hydroxy-2-pyridone alkaloid. The 
interesting aspect of leporin B is the bioactivity data obtained when tested against human 
breast carcinoma, MCF-7, human large cell lung carcinoma, NCI-H460, and human 
astrocytoma, SF-268. The IC50 values in μM for leporin B were 0.2, 0.1, and 0.2 
respectively. This data showed that leporin B is active against these three cancer cells and 
further study could lead to a potential drug compound. However, the challenge found 
from producing leporin B was the small supply. Therefore, optimizing production and 
obtaining potential analogues of leporin B was the goal.  
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Figure 5. Structures of Spiroscytalin, Leporin B, and Purpactin A (15) 
 
   
       1         2                 3 
 
 
Table 1. IC50 Values for Previously Isolated Compounds from MSX68345 (15) 
  
 
 
 
Leporin B, isolated from MSX68345, has shown good cytotoxicity against human breast 
carcinoma, human large cell lung carcinoma, and human astrocytoma, as shown above. In 
this context, and in order to increase the supply of this metabolite, a large scale 
fermentation (150 g of rice) of the strain was conducted. After the fermentation process, 
the organic extract was obtained using an established protocol. The organic extract was 
dereplicated to determine the existence of leporin B and assess potential for new 
compounds. Dereplication provided three compounds including: spirobotrin, alternariol 
monomethyl ether, penicillide, and vermixocin A. However, leporin B was not detected. 
However, the extract was further fractionated by flash chromatography. This procedure 
gave four fractions. A small aliquot of each organic extract and fractions were evaluated 
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for cytotoxicity in three different cancer cell lines, including: melanoma, breast and 
ovarian cancer cells. Cytotoxicity testing test a sample against three cancer cell lines 
using two concentrations of 20 µg/mL and 2 µg/mL of the sample. Boxes that show a 
number less than 50, means that less than half of the cancer cell survived with the 
addition of the sample. The cytotoxicity results showed very little activity in the large 
scale extract and the four flash chromatography fractions, as seen in table 2 where none 
of the boxes show a number less than 50, or less than 50% survival of those cancer cell 
lines. This data can be compared to the original extract cytotoxicity data that was tested 
against breast lung and astrocytoma cancer cell lines. The cancer cell lines vary, however, 
the original extract showed activity in three different cancer cell lines, therefore, it would 
be likely that the compound should show some activity in the other cancer cell lines as 
well, even if they are different types of cancer cells. Therefore, this was another sign that 
leporin B was not present in a significant amount or at all in the sample, due to the lack of 
activity in the new extract. For further confirmation, mass data on the organic extract and 
fractions was collected multiple times in search for leporin B, looking for the specific 
mass of leporin (352.19003 amu), but the mass was not found. Mass defect filtering was 
also performed in the hopes that it may just be in small supply or analogues may be 
present, but nothing was found. Looking back at the chromatogram for the small scale 
flash chromatography analysis (Fig. 7), there is a peak in between fraction 49-53. Based 
on the data that led to the original isolation of leporin B, that is the peak that should have 
contained leporin B. Looking at the flash chromatography for the large scale, the peaks in 
the beginning and end of the chromatogram relatively match up, but the peak for leporin 
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B, that should be around 22 minutes based on the chromatogram shown from the 
previous isolation, is missing (15). Therefore, it was determined that leporin B was not in 
that specific fermentations of Mycosythetix fungal strain 68345. 
 
Figure 6. Structures of Spirobotrin, Alternariol Monomethyl Ether, and Penicillide; 
Vermixocin A, Respectively 
  
 
 
 
Table 2. Cytotoxicity Data for the Original Organic Fraction Isolation of Leporin B 
and Current Cytotoxicity Data for Fractions Isolated from the Same Fungus 
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Figure 7. Flash Chromatography of Original Leporin B Isolation and Recent 
Isolation of Leporin B  
  
 
 
The next step in the search for leporin B was to obtain a slant growth of MSX68345 and 
another large scale. The four small scale slants and the large scale slants were extracted 
using the methods presented above. In order to save time and determine which of the five 
organic fractions to work with, each organic extract was analyzed through high resolution 
mass spectrometry, and the relative mass for leporin B was searched for. The data was 
processed using the software expressed above for mass defect filtering. The data showed 
the presence of the leporin B mass of 351.19003 in four of the five organic fractions,
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including the new large scale extract and three of the four small scale slants. Due to the 
presence of a nitrogen in the ring of leporin B, even numbered [M+H]+ peaks were 
recorded. Mass defect analysis provides data for potential analogue masses of the 
compound that is being searched for, therefore the even masses that were recorded were 
potential analogue matches. The next step was to analyze the masses through a molecular 
formula calculator. Molecular formulas, index of hydrogen deficiency values and parts 
per million values were all recorded. A number of molecular formulas were taken out of 
the list of potential analogues, as the changes were too drastic in relation to the core 
structure of leporin B. It was determined at this juncture to proceed with the large scale 
organic extract, due to the presence of the leporin B mass, potential for analogues, and 
more potential for increased mass of pure compounds.  
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Figure 8. Purification Fractions for MSX68345 
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Figure 9. Mass Spectrometry Data for Re-isolation of Leporin B  
 
 
 
 
It can be seen that fraction 15 from (Fig. 2) showed the presence of the leporin B [M+H]+ 
mass of 352.1908 amu. This mass can be confirmed by finding the [2M+1]+, which is 
703.38, a peak that can be seen in the mass spectrum above. To confirm the existence of 
leporin B, a proton NMR was performed and compared to the previous isolation proton 
NMR of leporin B. Therefore, fractions that showed the same proton NMR data were 
combined and further purified to obtain more pure sample of each compound. After 
further purification, additional NMR experimentation was done including: carbon and 
proton data. The carbon and proton data was matched with the previous isolation data to 
confirm the identity of leporin B. The fraction also contained 7.02 mg of sample, which 
can be combined with the previously isolated 2.49 mg to make 9.51 mg. The importance 
of the mass increase means that leporin B can be tested in vivo to determine if the 
compound acts in the same manner as it does with in vitro studies. 
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Leporin B  
White powder;  [α]D25-41.7 acetonitrile; 1H, 13C NMR data, see (Tables 3 and 4); 
HRESIMS m/z 352.1908 for [M+H]+ , calcd for C22H26NO3, 352.1907. 
The confirmation of the re-isolation of leporin B by NMR can be seen in (Fig. 9). 
The NMR experiments for leporin B were analyzed in deuterated chloroform on the 400 
MHz NMR. The NMR data between the isolated sample and the original sample are 
compared in (Tables 3 and 4).   
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Figure 10. Proton and Carbon NMR Data for Leporin B Both Past and Present 
Isolation 
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Table 3. Tabulated Proton NMR Data for Leporin B  
 
leporin 
B 
Literature    Experimental   
Position Proton 
shift 
Multiplicity J-value Proton Shift Multiplicity J-value
1 - - - - - - 
2 - - - - - - 
3 7.60 s - 7.59 s - 
4 - - - - - - 
5 - - - - - - 
6 - - - - - - 
7 2.79 dd 10,3.5 2.79 dd 10.85,
3.73 
8 1.77 m - 1.79 m - 
9a,b 1.60 m - 1.60 m - 
10a 1.51 m - 1.51 m - 
10b 1.39 tq 3.5,13 1.39 qt 12,4 
11a 1.76 m - 1.75 m - 
11b 1.60 m - 1.60 m - 
12 1.72 m - 1.75 m - 
13 4.82 dd 11,9 4.81 dd 11.22,
8.23 
14 5.37 ddq 15,8.6,2 5.36 ddq 15.20,
8.21,1.
56 
15 5.73 dq 16,7 5.73 dq 15.31,
6.55 
16 1.71 dd 7,2 1.72 dd 6.51,1.
64 
17 - - - - - - 
18 7.41 m - 7.41 m - 
19 7.37 m - 7.36 m - 
20 7.29 m - 7.30 m - 
21 7.37 m - 7.37 m - 
22 7.41 m - 7.41 m - 
23 0.86 d 6 0.86 d 6.53 
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Table 4. Tabulated Carbon NMR Data for Leporin B 
 
leporin B Literature  Experimental 
Position Carbon shift Carbon Shift 
1 158.2 158.40 
2 - - 
3 129.2 129.33 
4 111.2 111.16 
5 157.6 157.66 
6 113.7 113.53 
7 38.1 38.04 
8 35.9 35.92 
9a,b 35.8 35.81 
10a 20.9 20.85 
10b 20.9 20.85 
11a 26.5 26.50 
11b 26.5 26.50 
12 35.2 35.18 
13 78.2 78.21 
14 129.8 129.78 
15 131.2 131.21 
16 17.9 17.93 
17 133.7 133.72 
18 129.1 129.23 
19 128.3 128.35 
20 127.5 127.42 
21 128.3 128.35 
22 129.1 129.23 
23 20.4 20.43 
 
 
Analogue 
 
Continuing from fraction four of the large scale flash chromatography, fraction 
six of the HPLC purification showed the presence of a 336.19565 amu peak. This mass 
can be confirmed by the [2M+H]+ peak at 671.38422. The interesting aspect of this mass 
is the absence of an oxygen from the leporin B molecular formula. Therefore, the fraction 
was analyzed by proton and carbon NMR.  
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Figure 11. Mass Spectrum Leporin C 
 
 
 
 
Figure 12. Proton NMR Leporin C in Comparison to Proton NMR of Leporin B 
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Table 5. Tabulated Proton NMR Data for Leporin C 
 
 
leporin 
C 
Literature   Experimental   
Positio
n 
Proton 
shift 
Multiplicity J-value Proton shift Multiplicity J-value 
1 - - - - - - 
2 - - - - - - 
3 7.21 s - 7.16 s - 
4 -
  
- - - - - 
5 - - - - - - 
6 - - - - - - 
7 2.79 dd 10.9,3.7 2.77 dd 10.87,3
.77 
8 1.72 dd 6.5,1.5 1.80 m - 
9a,b 1.83-1.26 m - 1.58 m - 
10a 1.83-1.26 m - 1.41 m - 
10b 1.83-1.26 m - 1.27 m - 
11a 1.83-1.26 m - 1.76 m - 
11b 1.83-1.26 m - 1.58 m - 
12 1.83-1.26 m - 1.71 m - 
13 4.58 dd 11.3,8.1 4.84 dd 11.40,8
.24 
14 5.39 ddq 15.2,8.1,
1.5 
5.37 ddq 15.17,8
.26,1.8
3 
15 5.76 dq 15.2,6.5 5.73 dq 15.43,6
.49 
16 1.83-1.26 m - 1.71 dd 6.58,1.
62 
17 -  - - - - 
18 7.43-7.28 m - 7.40 m - 
19 7.43-7.28 m - 7.35 m - 
20 7.43-7.28 m - 7.28 m - 
21 7.43-7.28 m - 7.35 m - 
22 7.43-7.28 m - 7.40 m - 
23 1.01 d 6.5 1.00 d 6.58 
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Table 6. Tabulated Carbon NMR Data for Leporin C 
 
leporin C Literature Experimental 
Position Carbon shift Carbon shift 
1 165.2 164.70 
2 - - 
3 129.7 129.51 
4 111.7 111.62 
5 160.5 160.51 
6 115.3 115.44 
7 37.3 37.09 
8 36.2 36.05 
9a,b 36.1 35.90 
10a 21.1 20.98 
10b 21.1 20.98 
11a 26.7 26.58 
11b 26.7 26.58 
12 35.4 35.22 
13 78.3 78.25 
14 131.0 131.01 
15 131.8 131.29 
16 18.0 17.94 
17 134.7 134.43 
18 129.3 129.14 
19 128.3 128.23 
20 127.2 127.15 
21 128.3 128.23 
22 129.3 129.14 
23 20.7 20.60 
 
 
Leporin C was compared by NMR, as shown in (Fig. 11) and (Tables 5 and 6).  
Additional Compounds 
Leporin B was re-isolated from MSX68345, however, there were a number of 
other fractions that could be purified from the fungus that showed promise in that the 
fractions were somewhat pure and there was enough material to work with. A particular 
set of fractions showed interesting HPLC chromatograms with UV data. The UV data 
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was interesting due to the fact that it was showing absorbance’s at three different 
wavelengths as opposed to the typical two. Therefore, those fractions were further 
purified. During the purification process, fractions five and six crystalized. The crystals 
from fraction five were good enough to send for x-ray crystallography. The data was 
analyzed and the compound was found to be the known compound, austdiol, as seen in 
(Fig. 2). To confirm this structure, proton NMR was performed on the structure and 
confirmed the austdiol structure. The fraction 6 also crystalized, however the crystals 
were too small for x-ray crystallography. Therefore, a proton NMR was performed on the 
sample. As seen in (Fig. 12), the proton NMR data matches up with the exception of the 
aromatic peaks around 8 ppm. The mass data was also the same for both fractions, 
showing a mass of 237.07 amu and an index of hydrogen deficiency of seven. The 
interesting aspect about this process was a color change that occurred when the sample 
was dissolved in chloroform. The sample went from a yellowish color to a blue color. 
Fraction six also changed to a green color. The fractions did not dissolve well with 
chloroform, so DMSO was needed to dissolve the samples. Figure 13 shows the initial 
crystals in the vial and the fractions transformation to various colors when further 
dissolved in DMSO. The following picture shows the sample in the NMR tubes and the 
final picture shows the samples after leaving them in the NMR tubes overnight. In each 
case, the color seemed to transform to darker and darker colors as time passed. A possible 
explanation for this could be the degradation of the compound, which would affect the 
number of conjugated pi electrons in the structure. Loss of the aldehyde would be a 
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potential point of degradation that would affect the conjugated π electrons, which would 
affect the light that is absorbed, causing a color change.  
 
Figure 13. Proton NMR Data Compared for Austdiol and 7-epi-Austdiol  
 
 
 
 
Figure 14. Photos of Austdiol and 7-epi-Austdiol in Crystal and Color Altered Forms  
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Table 7. Tabulated Proton NMR Data for Austdiol 
 
 
 
austdiol Literature  Experimental  
Position Proton shift Multiplicity Proton shift Multiplicity 
1 8.19 - 8.26 s 
3 - - - - 
4 8.19 - 8.16 s 
4a - - - - 
5 - - - - 
6 - - - - 
7 - - - - 
7-OH 5.25 S 4.99 s 
8  4.39 S 4.27 s 
8a - - - - 
8-OH 5.92 S 5.57 s 
9 2.21 S 2.37 s 
10 9.99 - 9.94 s 
11 1.08 S 1.09 s 
 
 
Austdiol  
 Yellow crystals; [α]D2868.9 DMSO; 1H, 13C NMR data, see (Table 7); HRESIMS m/z 
237.0756 for [M+H]+ , calcd for C12H13O5, 237.0757. 
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Table 8. Tabulated Proton NMR Data for 7-epi-Austdiol  
 
 
 
7-epi-austdiol Literature   Experimental  
Position Proton shift Multiplicity J-value Proton shift Multiplicity
1 8.28 S - 8.17 s 
3 - - - - - 
4 8.19 S - 8.16 s 
5 - - - - - 
6 - - - - - 
7 - - - - - 
7-OH 4.94 S - 5.27 s 
8 4.31 D 4.0 4.36 s 
8-OH 5.50 D 4.0 5.95 s 
9 - - - - - 
10 - - - - - 
11 2.41 S - 2.37 s 
12 9.98 S - 9.96 s 
13 1.14 S - 1.04 s 
 
 
7-epi-austdiol   
Yellow crystals; [α]D28202.8 DMSO; 1H, 13C NMR data, see (Table 8); HRESIMS m/z 
237.0755 for [M+H]+ , calcd for C12H13O5, 237.0757. 
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CHAPTER V 
 
BENZOISOQUINOLINE 
 
 
Fungus MSX68345 was the specific fungus that led to the re-isolation of leporin 
B, however there are other Mycosynthetix fungi that can be studied for secondary 
metabolites that are active against varying cancer cells. One fungus, MSX74367, was one 
of the fungi that produced good activity against melanoma, breast, and ovarian cancer 
cell lines. Table 9, shows the activity of the sample material and the three fractions 
created after flash chromatography. Active fractions will show less than 50% survival of 
the different cancer cell lines. Therefore, fraction three is highlighted in red due to its 
good activity, less than 50% survival, in the 20 µg/mL concentration for all three cancer 
cell lines. Fraction three was further purified to determine the active compound by using 
flash chromatography as seen in (Fig. 3). Further purification by HPLC of fraction three 
showed the presence of a known compound, 9-O-methylbostrycoidin. 
 
Figure 15. Structure of 9-O-Methylbostrycoidin  
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Table 9. Cytotoxicity Data for MSX74367  
 
 
 
 
Figure 16. Purification Fractions for MSX74367 
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The mass spectrum for the purified fraction showed a mass of 300.08609 amu. This mass 
can be confirmed by the 322.06763 amu mass, which represents the addition of sodium. 
This mass is also within 5 ppm of the calculated mass for the compound and shows a 
degree of unsaturation of 11. The proton NMR data was matched with previously isolated 
9-O-methylbostrycoidin (Fig. 15 and Table 10). 
 
Figure 17. Mass Spectrometry and Proton NMR Data for 9-O-Methylbostrycoidin 
 
 
46 
 
Table 10. Tabulated Proton NMR Data for 9-O-Methylbostrycoidin 
 
 
 
9-O-
methylbostrycoidin 
Literature  Experimental  
Position Proton shift Multiplicity Proton shift Multiplicity 
1 9.44 S 9.45 s 
3 - - - - 
4 7.85 S 7.86 s 
5 - - - - 
6 - - - - 
7 6.86 S 6.89 s 
8 - - - - 
9 - - - - 
10 - - - - 
11 - - - - 
12 - - - - 
13 - - - - 
14 - - - - 
15 2.76 S 2.75 s 
6-OCH3 4.05 S 4.05 s 
8- OCH3 4.05 S 4.05 s 
OH 13.19 S 13.28 s 
 
 
Another fraction was purified from the same fungus to isolate the compound 8-O-
methyl-fusarubin. The mass spectrum shows a mass of 321.09598 amu. This mass was 
confirmed by the peak showing the loss of water, (303.08545 amu peak). The compound 
mass is shown to be within 5 ppm of the calculated mass, with an index of hydrogen 
deficiency of 9. Proton NMR data was obtained for the compound and matched through 
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dictionary of natural products with the known compound 8-O-methyl-fusarubin (Fig. 16 
and Table 11).   
 
Figure 18. Mass Spectrometry and Proton NMR Data for 8-O-Methyl-Fusarubin 
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Table 11. Tabulated Proton NMR Data for 8-O-Methyl-Fusarubin 
 
 
 
8-O-
methyl-
fusarubin 
Literature   Experimental   
Position Proton 
shift 
Multiplicit
y 
J-
value 
Proton shift Multiplicity J-
value 
1 4.75 dd 18,2.
8 
4.72 m - 
3 - - - - - - 
4ax 2.53 d 18 2.53 dd 20.16,
4.18 
4eq 2.84 d 18 2.85 dd 18.58,
2.45 
5-OH 13.16 s - 13.16 s - 
6 - - - - - - 
6-OMe 4.03 s - 3.98 s - 
7 6.73 s - 6.72 s - 
8 - - - - - - 
8-OMe  4.00 s - 4.01 s - 
9 - - - - - - 
10 - - - - - - 
11 - - - - - - 
12 - - - - - - 
13 - - - - - - 
14 - - - - - - 
15 1.55 s - 2.21 d 2.13 
 
 
A large scale growth of MSX74367 was obtained. The new goal was to specify 
the purification process towards obtaining benzoisoquinoline containing compounds and 
nitrogen containing compounds. In order to do this, mass defect filtering was performed. 
Masses were chosen based on even [M+H]+ values, which are representative of nitrogen 
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containing compounds. The list of masses was narrowed down to masses that could 
represent the addition or loss of substituents on the outside of the core structure of 9-O-
methylbostrycoidin. This list is shown in (Table 12), where green numbers represent the 
addition of substituents, red numbers show the subtraction of substituents, and black 
numbers show the same mass as 9-O-methylbostrycoidin. The black numbers could 
represent analogues of the compound, or they could represent the compound bleeding 
through the varying fractions. The list of masses obtained through mass defect filtering 
were correlated with high resolution mass spectrometry of each stage of purification of 
the large scale growth. This process allowed for guided fractionation of compounds 
found in the large scale. The advantage of this process was the re-isolation of 9-O-
methylbostrycoidin, however the disadvantage was that other nitrogen containing 
analogues were not obtained. Based on this analysis, it may have been better to perform a 
cytotoxicity guided fractionation. This would have been more time consuming, however 
it may have resulted in more interesting compounds from this fungus.  
 
Figure 19. Flow Chart for Benzoisoquinoline Mass Guided Fractionation  
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Table 12. MDF Data Collected from Screener Scale Fractions  
 
 
 
 
Figure 20. Purification Fractions for MSX74367   
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CHAPTER VI 
 
CONCLUSIONS 
 
 
Two fungal species, MSX68345 and MSX74367, were studied. The study of 
secondary metabolites from fungal species MSX68345 led to the re-isolation of leporin B 
and the increase of the in house supply. A new natural product was also isolated, leporin 
C, which is just the absence of the oxygen group in position two. Other compounds 
isolated from Scytalidium cuboideum were austdiol and 7-epi-austdiol. Re-isolation of 
leporin B was the main goal due to its activity against breast, lung, and astrocytoma 
cancer cell lines. With the increased supply of leporin B from less than three mg to 
approximately 10 mg, the compound can now be used for further testing in vivo. Leporin 
C was also found from the same fungus. It is a known compound from the synthesis of 
leporin A, however, it is new to natural product isolation (13). Leporin C can be added to 
the in house database of over 300 compounds. Finding this compound and leporin B 
could mean that other analogues are present in Scytalidium cuboideum. Austdiol and 7-
epi-austdiol were also isolated from MSX68345. Fungal species MSX74367 was another 
fungal species that was  
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interesting to study due to it containing benzoisoquinoline structures, something that is 
lacking with the in house database of over 300 compounds. The fungus also produced the 
compound 8-O-methylfusarubin, which has the same core structure as 9-O-
methylbostrycoidin with the loss of the nitrogen.   
 
Figure 21. All Characterized Structures  
 
Leporin B 9-O-methylbostrycoidin
8-O-methyl-Fusarubin
Austdiol 7-epi-Austdiol
Leporin C
MSX68345 MSX74367
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